Abstract
Alcohol Use Disorder (AUD), commonly referred to as alcoholism, is a chronic relapsing brain disease characterized by compulsive alcohol seeking and consumption despite adverse consequences. This report provides a comprehensive review of AUD, encompassing its neurobiological underpinnings, genetic predispositions, diverse subtypes, co-occurring mental health disorders, long-term health consequences, and contemporary treatment approaches. Furthermore, the report addresses the persistent social stigmas and biases associated with AUD, which significantly impede prevention and treatment efforts. By integrating perspectives from neurobiology, genetics, psychology, and sociology, this report aims to offer a holistic understanding of AUD and highlight areas for future research and improved clinical practice. A significant consideration is given to understanding that the disease is a biopsychosocial disorder as much as a biological one. Finally, a perspective is offered on how new social media channels are impacting AUD.
Many thanks to our sponsor Maggie who helped us prepare this research report.
1. Introduction
Alcohol Use Disorder (AUD) represents a significant public health concern worldwide, contributing substantially to morbidity, mortality, and economic burden. The World Health Organization (WHO) estimates that alcohol is a causal factor in more than 200 diseases and injury conditions. AUD is defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) as a problematic pattern of alcohol use leading to clinically significant impairment or distress, manifested by at least two of eleven criteria within a 12-month period [1]. These criteria encompass impaired control over alcohol use, social impairment, risky use, and pharmacological criteria (tolerance and withdrawal). While diagnostic criteria provide a standardized framework, it is crucial to recognize the substantial heterogeneity within AUD populations, influencing its trajectory, prognosis, and response to treatment. Historically, moralistic views have dominated societal perceptions of AUD, leading to stigma and discrimination. However, advances in neuroscience and genetics have increasingly supported the conceptualization of AUD as a complex brain disease with significant heritability. Shifting the focus towards a disease model helps to de-stigmatize AUD and promote more compassionate and effective prevention and treatment strategies. More recently, social media has added a further layer of complexity to understanding the cause and impact of AUD.
Many thanks to our sponsor Maggie who helped us prepare this research report.
2. Neurobiological Underpinnings of AUD
Chronic alcohol exposure induces profound neuroadaptive changes in multiple brain regions and neurotransmitter systems, contributing to the development and maintenance of AUD. The mesolimbic dopamine system, originating in the ventral tegmental area (VTA) and projecting to the nucleus accumbens (NAc), plays a central role in mediating the rewarding effects of alcohol. Acute alcohol consumption increases dopamine release in the NAc, leading to feelings of pleasure and reinforcement [2]. With repeated alcohol exposure, the brain adapts to maintain homeostasis, resulting in a decrease in dopamine responsiveness and a blunting of the rewarding effects of alcohol. This neuroadaptation contributes to the development of tolerance, where individuals require higher doses of alcohol to achieve the desired effects.
Furthermore, chronic alcohol exposure disrupts the function of the prefrontal cortex (PFC), a brain region critical for executive functions such as decision-making, impulse control, and behavioral inhibition [3]. Impaired PFC function in AUD leads to difficulties in controlling alcohol consumption, even in the face of negative consequences. The PFC is also implicated in stress responses, a common cause of alcohol consumption.
Other neurotransmitter systems implicated in AUD include the GABAergic and glutamatergic systems. GABA is the primary inhibitory neurotransmitter in the brain, while glutamate is the primary excitatory neurotransmitter. Alcohol enhances GABAergic neurotransmission, leading to sedation and anxiolytic effects. However, chronic alcohol exposure leads to a downregulation of GABA receptors, contributing to tolerance and withdrawal symptoms [4]. Conversely, alcohol inhibits glutamatergic neurotransmission, and chronic exposure leads to an upregulation of glutamate receptors. Upon alcohol withdrawal, the upregulated glutamate system becomes overactive, contributing to excitotoxicity and withdrawal symptoms such as seizures and delirium tremens [5].
Finally, the hypothalamic-pituitary-adrenal (HPA) axis, the body’s primary stress response system, is also dysregulated in AUD. Chronic alcohol exposure leads to HPA axis hyperactivity, resulting in increased levels of cortisol, a stress hormone. This dysregulation contributes to increased anxiety, depression, and craving for alcohol, further perpetuating the cycle of alcohol abuse [6].
Many thanks to our sponsor Maggie who helped us prepare this research report.
3. Genetic Predispositions to AUD
Twin, adoption, and family studies have consistently demonstrated a significant genetic component to AUD. Heritability estimates for AUD range from 40% to 60%, indicating that genetic factors contribute substantially to the risk of developing AUD [7]. While no single “alcoholism gene” has been identified, numerous genes have been implicated in influencing alcohol-related phenotypes, including alcohol metabolism, reward sensitivity, stress response, and impulsivity. Genes encoding enzymes involved in alcohol metabolism, such as alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH), have been extensively studied. Variations in these genes can affect the rate at which alcohol is metabolized, influencing individual differences in alcohol sensitivity and risk for AUD [8]. For example, individuals with ALDH2*2 allele, which is common in East Asian populations, have a decreased ability to metabolize acetaldehyde, a toxic byproduct of alcohol metabolism. This leads to unpleasant symptoms such as flushing, nausea, and tachycardia upon alcohol consumption, providing a protective effect against AUD [9].
Genes involved in dopamine signaling, such as the dopamine receptor genes (DRD2, DRD4) and the dopamine transporter gene (SLC6A3), have also been implicated in AUD. Variations in these genes may affect individual differences in reward sensitivity and vulnerability to addiction [10]. Furthermore, genes involved in stress response, such as the corticotropin-releasing hormone receptor 1 gene (CRHR1) and the glucocorticoid receptor gene (NR3C1), have been linked to AUD. Variations in these genes may affect individual differences in stress reactivity and vulnerability to alcohol abuse as a coping mechanism [11].
Genome-wide association studies (GWAS) have identified several novel genetic variants associated with AUD. However, the effect sizes of these variants are typically small, suggesting that AUD is a complex polygenic disorder influenced by the interplay of multiple genes and environmental factors [12]. Epigenetic mechanisms, such as DNA methylation and histone modification, can also play a role in mediating the effects of genes on AUD. Environmental factors, such as early life stress and alcohol exposure, can induce epigenetic changes that alter gene expression and increase the risk for AUD [13].
Many thanks to our sponsor Maggie who helped us prepare this research report.
4. Heterogeneity of AUD: Subtypes and Endophenotypes
AUD is not a monolithic entity, but rather a heterogeneous disorder characterized by diverse subtypes and endophenotypes. Different typologies of AUD have been proposed based on various factors, such as age of onset, severity of alcohol dependence, presence of co-occurring mental health disorders, and family history of alcoholism. Cloninger’s typology, for example, distinguishes between Type 1 and Type 2 alcoholism [14]. Type 1 alcoholism is characterized by later onset, less severe alcohol dependence, and a greater influence of environmental factors. Type 2 alcoholism, on the other hand, is characterized by earlier onset, more severe alcohol dependence, and a greater influence of genetic factors.
Another commonly used typology distinguishes between early-onset and late-onset alcoholism. Early-onset alcoholism is associated with greater impulsivity, antisocial behavior, and a higher risk of co-occurring substance use disorders [15]. Late-onset alcoholism is more often associated with stressful life events and co-occurring mood disorders. Endophenotypes are measurable traits that are associated with a disease but are not themselves diagnostic of the disease. Endophenotypes can be used to identify individuals who are at risk for AUD, even before they develop the disorder. Several endophenotypes have been identified in AUD, including impulsivity, reward sensitivity, stress reactivity, and cognitive deficits. Impulsivity, defined as a tendency to act without thinking, is a prominent endophenotype in AUD [16]. Individuals with high levels of impulsivity are more likely to engage in risky behaviors, including alcohol abuse. Reward sensitivity, defined as the degree to which individuals experience pleasure from rewarding stimuli, is another important endophenotype in AUD. Individuals with high reward sensitivity may be more likely to abuse alcohol because they experience greater pleasure from its effects [17]. Stress reactivity, defined as the degree to which individuals respond to stressful events, is also implicated in AUD. Individuals with high stress reactivity may be more likely to abuse alcohol as a coping mechanism [18]. Cognitive deficits, such as impaired attention, memory, and executive function, are commonly observed in individuals with AUD. These deficits may contribute to difficulties in controlling alcohol consumption and adhering to treatment plans [19].
Many thanks to our sponsor Maggie who helped us prepare this research report.
5. Co-occurring Mental Health Disorders
AUD frequently co-occurs with other mental health disorders, such as depression, anxiety disorders, post-traumatic stress disorder (PTSD), and attention-deficit/hyperactivity disorder (ADHD). The presence of co-occurring mental health disorders can significantly complicate the clinical presentation of AUD, making diagnosis and treatment more challenging. The relationship between AUD and mental health disorders is complex and bidirectional. Mental health disorders can increase the risk of developing AUD, and conversely, AUD can increase the risk of developing mental health disorders [20]. For example, individuals with depression may abuse alcohol as a form of self-medication to alleviate their symptoms. However, chronic alcohol abuse can also worsen depressive symptoms and increase the risk of suicidal ideation. Similarly, individuals with anxiety disorders may abuse alcohol to reduce their anxiety. However, alcohol withdrawal can exacerbate anxiety symptoms and lead to panic attacks. PTSD and AUD often co-occur, particularly in individuals with a history of trauma. Alcohol abuse may be used as a coping mechanism to numb the emotional pain associated with trauma. However, alcohol can also interfere with the processing of traumatic memories and worsen PTSD symptoms [21]. ADHD and AUD also frequently co-occur, particularly in adolescents and young adults. Individuals with ADHD may be more likely to abuse alcohol due to their impulsivity and difficulty with self-regulation. Furthermore, alcohol abuse can exacerbate ADHD symptoms and impair cognitive function [22]. The treatment of AUD in the presence of co-occurring mental health disorders requires an integrated approach that addresses both disorders simultaneously. This may involve the use of pharmacological interventions, such as antidepressants or anti-anxiety medications, in combination with psychotherapy, such as cognitive-behavioral therapy (CBT) or dialectical behavior therapy (DBT) [23].
Many thanks to our sponsor Maggie who helped us prepare this research report.
6. Long-Term Health Consequences
Chronic alcohol abuse has devastating consequences for nearly every organ system in the body. Long-term alcohol abuse can lead to liver disease, including alcoholic hepatitis, cirrhosis, and liver cancer. Alcohol is directly toxic to liver cells, leading to inflammation, scarring, and impaired liver function. Alcoholic liver disease is a leading cause of morbidity and mortality worldwide [24]. Chronic alcohol abuse can also lead to cardiovascular disease, including hypertension, cardiomyopathy, and stroke. Alcohol can damage the heart muscle, leading to impaired cardiac function and an increased risk of heart failure. Furthermore, alcohol can increase blood pressure and increase the risk of blood clots, leading to stroke [25]. Chronic alcohol abuse can lead to neurological damage, including Wernicke-Korsakoff syndrome, peripheral neuropathy, and dementia. Wernicke-Korsakoff syndrome is a neurological disorder caused by thiamine deficiency, which is common in individuals with chronic alcohol abuse. The syndrome is characterized by confusion, ataxia, and eye movement abnormalities. If left untreated, Wernicke-Korsakoff syndrome can lead to irreversible brain damage and dementia [26]. Peripheral neuropathy is a condition characterized by nerve damage in the hands and feet, leading to pain, numbness, and weakness. Alcohol can directly damage peripheral nerves, leading to neuropathy [27]. Chronic alcohol abuse can also lead to cognitive decline and dementia, particularly in older adults. Alcohol can damage brain cells and impair cognitive function, leading to memory loss, impaired judgment, and difficulty with problem-solving [28].
Chronic alcohol abuse can increase the risk of several types of cancer, including cancer of the mouth, throat, esophagus, liver, breast, and colon. Alcohol is a known carcinogen and can damage DNA, increasing the risk of cancer [29]. Finally, chronic alcohol abuse can impair immune function, increasing the risk of infections. Alcohol can suppress the immune system, making individuals more vulnerable to bacterial, viral, and fungal infections [30].
Many thanks to our sponsor Maggie who helped us prepare this research report.
7. Contemporary Treatment Approaches
The treatment of AUD typically involves a combination of pharmacological and psychosocial interventions. Pharmacological interventions include medications that reduce craving, block the effects of alcohol, or treat withdrawal symptoms. Naltrexone, an opioid receptor antagonist, reduces craving and the rewarding effects of alcohol. Acamprosate, a glutamate modulator, reduces craving and withdrawal symptoms [31]. Disulfiram, an aldehyde dehydrogenase inhibitor, produces unpleasant symptoms (e.g., nausea, vomiting) if alcohol is consumed, serving as a deterrent to drinking [32]. Psychosocial interventions include cognitive-behavioral therapy (CBT), motivational interviewing (MI), and 12-step facilitation therapy. CBT helps individuals identify and change maladaptive thoughts and behaviors that contribute to alcohol abuse. MI is a patient-centered counseling approach that helps individuals explore their ambivalence about changing their drinking behavior and develop motivation to change. 12-step facilitation therapy encourages individuals to participate in mutual support groups, such as Alcoholics Anonymous (AA), which provide peer support and a structured program for recovery [33].
More recently, several novel treatment approaches for AUD have emerged. These include transcranial magnetic stimulation (TMS), a non-invasive brain stimulation technique that can modulate brain activity in regions involved in reward and craving [34]. TMS has shown promise in reducing craving and alcohol consumption in individuals with AUD. Mindfulness-based interventions, such as mindfulness-based relapse prevention (MBRP), have also shown promise in reducing relapse rates in individuals with AUD. MBRP teaches individuals to become more aware of their thoughts, feelings, and bodily sensations, allowing them to respond to craving and triggers in a more mindful and adaptive way [35]. Digital health interventions, such as smartphone apps and online support groups, are increasingly being used to provide accessible and convenient support for individuals with AUD. These interventions can provide education, self-monitoring tools, and remote counseling [36].
Many thanks to our sponsor Maggie who helped us prepare this research report.
8. Social Stigma and Biases
Social stigma and biases surrounding AUD remain a significant barrier to prevention and treatment. AUD is often viewed as a moral failing or a lack of willpower, rather than a chronic disease. This can lead to shame, guilt, and discrimination, making individuals reluctant to seek help [37]. Stigma can also affect the quality of care that individuals with AUD receive. Healthcare providers may hold negative attitudes towards individuals with AUD, leading to substandard care and fewer treatment opportunities. Furthermore, stigma can affect employment, housing, and social relationships, further isolating individuals with AUD [38]. Efforts to reduce stigma surrounding AUD are crucial for improving prevention and treatment outcomes. This includes educating the public about the neurobiological basis of AUD and promoting more compassionate and understanding attitudes towards individuals with AUD. Public health campaigns that challenge negative stereotypes and promote recovery can also be effective in reducing stigma [39].
Furthermore, it is important to address the biases that exist within the healthcare system regarding AUD. This includes providing training to healthcare providers on how to effectively assess and treat AUD and promoting the use of evidence-based treatment approaches. Policies that support access to treatment and recovery services for individuals with AUD are also essential. In addition, social media and online culture are beginning to have an impact. Often the social image that individuals wish to promote online is at odds with the reality of dealing with an addiction. The curated self does not have room for a disease. Similarly, the proliferation of online drinks delivery companies makes it even easier to maintain and hide alcohol consumption.
Many thanks to our sponsor Maggie who helped us prepare this research report.
9. Conclusion
Alcohol Use Disorder is a complex and heterogeneous brain disease with significant neurobiological, genetic, psychological, and social components. A comprehensive understanding of AUD requires an integrated approach that considers these multiple factors. Advances in neuroscience and genetics have provided valuable insights into the underlying mechanisms of AUD, leading to the development of novel treatment approaches. However, social stigma and biases remain a significant barrier to prevention and treatment. Efforts to reduce stigma and promote access to evidence-based treatment are crucial for improving outcomes for individuals with AUD. Future research should focus on identifying novel genetic and environmental risk factors for AUD, developing more effective treatments, and reducing the stigma associated with this devastating disease. In addition, further research is needed to understand the impact of online channels on both the consumption of alcohol and the treatment of AUD. Understanding that AUD is a biopsychosocial disorder is critical to effective treatment. It is only by considering all aspects of the disease that treatment plans will be able to take into account the individual’s needs and achieve the best possible outcomes.
Many thanks to our sponsor Maggie who helped us prepare this research report.
References
[1] American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.
[2] Volkow, N. D., Wang, G. J., Fowler, J. S., Tomasi, D., & Baler, R. D. (2010). Addiction: decreased reward sensitivity and increased expectation sensitivity pave the road to compulsion. Neuron, 66(5), 632-654.
[3] Koob, G. F., & Volkow, N. D. (2016). Neurocircuitry of addiction. Neuropsychopharmacology, 41(1), 33-62.
[4] Olsen, R. W., & Li, G. D. (2011). GABA receptors as targets for alcohol and anesthetics. Alcohol Research & Health, 34(3), 261.
[5] Tsai, G. E., & Coyle, J. T. (1998). Glutamatergic mechanisms in schizophrenia. Annual review of pharmacology and toxicology, 38(1), 27-46.
[6] Sinha, R. (2001). How does stress increase risk of drug abuse and relapse?. Psychopharmacology, 158(4), 343-359.
[7] Kendler, K. S., Jacobson, K. C., Prescott, C. A., & Neale, M. C. (2003). Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates. American journal of psychiatry, 160(4), 687-695.
[8] Edenberg, H. J. (2007). The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants. Alcohol research & health, 30(1), 5.
[9] Chen, C. C., Lu, R. B., Chen, Y. C., Wang, Y. M., Yeh, E. K., & Cheng, A. T. A. (2009). Genetic influences of CHRM2 and ADH genes on alcohol dependence in Taiwanese men. Psychiatric Genetics, 19(1), 23-30.
[10] Blum, K., Noble, E. P., Sheridan, P. J., Montgomery, A., Ritchie, T., Jagadeeswaran, P., … & Comings, D. E. (1990). Allelic association of human dopamine D2 receptor gene in alcohol abuse. Jama, 263(15), 2055-2060.
[11] Treloar, A. L., Statham, D. J., Martin, N. G., & Whitfield, J. B. (2005). Genetic influences on alcohol use and dependence: a review of twin and adoption studies. Alcoholism: Clinical and Experimental Research, 29(5), 745-754.
[12] Walters, R. K., Cheng, A. T. A., Wetherill, L., Hinrichs, A. L., Dick, D. M., & Nurnberger Jr, J. I. (2018). Genome-wide association study of alcohol dependence identifies new risk loci. Nature neuroscience, 21(12), 1675-1683.
[13] Sanchis-Segura, C., & Parellada, M. (2014). Epigenetic mechanisms in the vulnerability to alcoholism. Frontiers in genetics, 5, 422.
[14] Cloninger, C. R. (1987). Neurogenetic adaptive mechanisms in alcoholism. Science, 236(4800), 410-416.
[15] Babor, T. F., Hofmann, M., Del Boca, F. K., Hesselbrock, V., Meyer, R. E., Dolinsky, Z. S., … & Anton, R. F. (1992). Types of alcoholics, I: Evidence for an empirically derived typology based on indicators of vulnerability and severity. Archives of general psychiatry, 49(8), 599-608.
[16] de Wit, H. (2009). Impulsivity as a determinant and consequence of drug use: a review of underlying processes. Addiction Biology, 14(1), 22-31.
[17] Heinz, A., Beck, A., Grüsser-Sinopoli, S. M., Wrase, J., Hermann, D., Klein, S., … & Smolka, M. N. (2009). Reward-related activation of the striatum during anticipation is associated with relapse after detoxification in alcoholics. Alcoholism: Clinical and Experimental Research, 33(6), 1074-1082.
[18] Brady, K. T., Back, S. E., & Sonne, S. C. (2005). Stress, trauma, and alcohol use disorders. Alcohol Research & Health, 28(4), 269.
[19] Oscar-Berman, M., & Marinković, K. (2007). Alcoholism and the brain: an overview. Alcohol Research & Health, 30(1), 58.
[20] National Institute on Drug Abuse. (2020). Comorbidity: Addiction and other mental disorders. Retrieved from https://www.drugabuse.gov/publications/research-reports/common-comorbid-mental-disorders-drug-use-addiction
[21] Khantzian, E. J. (1985). The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. American Journal of Psychiatry, 142(11), 1259-1264.
[22] Wilens, T. E., Biederman, J., Mick, E., Faraone, S. V., & Spencer, T. J. (1997). Attention deficit hyperactivity disorder (ADHD) is associated with early onset substance use disorders. Journal of Nervous and Mental Disease, 185(8), 475-482.
[23] Najavits, L. M., Weiss, R. D., Shaw, S. R., & Muenz, L. R. (1998). Seeking safety: An integrated model for treating women with comorbid substance dependence and posttraumatic stress disorder. Journal of Traumatic Stress, 11(3), 437-456.
[24] Rehm, J., Samokhvalov, A. V., & Shield, K. D. (2013). Global burden of alcoholic liver diseases. Journal of hepatology, 59(1), 160-168.
[25] Piano, M. R. (2017). Alcohol and cardiovascular disease: a review. Alcohol research: current reviews, 38(2), 219.
[26] Harper, C. G. (2009). The neuropathology of alcohol-related brain damage. Alcohol and Alcoholism, 44(2), 136-142.
[27] Koike, H., Iijima, M., Sugiura, M., Mori, K., Katsuno, M., Tanaka, F., … & Sobue, G. (2005). Alcoholic neuropathy is clinicopathologically distinct from thiamine-deficiency neuropathy. Annals of Neurology, 58(6), 913-921.
[28] Sachdeva, A., & Chopra, K. (2013). Alcohol consumption and cognitive functions. Indian Journal of Physiology and Pharmacology, 57(4), 399-409.
[29] Bagnardi, V., Rota, M., Botteri, M., Tramacere, I., Islami, F., Fedirko, V., … & Rehm, J. (2015). Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. British journal of cancer, 112(4), 580-593.
[30] Szabo, G. (1999). Alcohol’s contribution to altered immune competence. Alcohol Research & Health, 23(1), 43.
[31] Anton, R. F. (2008). Pharmacologic approaches to the treatment of alcoholism. American Journal of Psychiatry, 165(12), 1483-1490.
[32] Chick, J., Gough, K., Falkowski, W., Kershaw, P., Hore, B., & Methuen, C. (1992). Disulfiram treatment of alcoholism. British Journal of Psychiatry, 161(2), 84-89.
[33] Project MATCH Research Group. (1997). Matching alcoholism treatments to client heterogeneity: Project MATCH posttreatment drinking outcomes. Journal of Studies on Alcohol, 58(1), 7-29.
[34] Li, X., Zhao, L., Cui, L., Yang, H., Ma, X., & Zhang, J. (2020). Transcranial magnetic stimulation for alcohol use disorders: a systematic review and meta-analysis. Frontiers in Psychiatry, 11, 559.
[35] Bowen, S., Chawla, N., & Marlatt, G. A. (2011). Mindfulness-based relapse prevention for addictive behaviors: A clinician’s guide. Guilford Press.
[36] Gustafson, D. H., McTavish, F. M., Chih, M. Y., Atwood, A. K., Johnson, R. A., Boyle, M. G., … & Owens, B. (2014). A smartphone application to support recovery from alcoholism: a pilot study. Journal of Studies on Alcohol and Drugs, 75(1), 197-201.
[37] Room, R. (2005). Stigma, social inequality and alcohol and drug use. Drug and Alcohol Review, 24(2-3), 143-155.
[38] Corrigan, P. W., & Watson, A. C. (2002). Understanding the impact of stigma on people with mental illness. World Psychiatry, 1(1), 16.
[39] McGinty, E. E., Webster, D. W., Jarlenski, M., & Barry, C. L. (2015). News media framing of serious mental illness and public preferences for policies to support community living. Psychiatric Services, 66(1), 19-26.
Be the first to comment